Sarilumab: A Complete Medical Overview

Sarilumab is a prescription biologic medicine that blocks interleukin-6 (IL-6), an immune-system protein involved in inflammation. It is mainly used for certain adults with moderately to severely active rheumatoid arthritis when other treatments have not worked well enough or are not suitable.

What is sarilumab?

Sarilumab is a biologic disease-modifying antirheumatic drug, often called a biologic DMARD. It is a targeted medicine that reduces inflammatory activity by blocking the receptor for interleukin-6 (IL-6). IL-6 is a signaling protein made by the immune system. In people with inflammatory autoimmune conditions, excessive IL-6 signaling can contribute to joint swelling, pain, stiffness and ongoing tissue damage.

The medicine is administered by injection under the skin, usually using a prefilled syringe or pen. The exact schedule, injection technique and whether a person can inject at home are decided by the prescribing clinician. Sarilumab is available only with a prescription and should be used under the supervision of a clinician experienced in treating inflammatory disease.

It is not a painkiller that gives immediate relief, and it does not cure rheumatoid arthritis. Instead, it aims to control the immune-driven inflammation that causes symptoms and may lead to progressive joint damage. Response varies between individuals, and benefit may take several weeks to become clear.

What conditions is sarilumab used for?

Sarilumab is primarily used to treat adults with moderately to severely active rheumatoid arthritis. It may be considered when conventional DMARDs, such as methotrexate, have not provided adequate control, are not tolerated or are medically unsuitable. Depending on the treatment plan, it may be used with methotrexate or on its own.

Rheumatoid arthritis is an autoimmune condition in which the immune system mistakenly attacks the lining of the joints. This can cause persistent pain, warmth, swelling, morning stiffness and reduced function. Without effective control, inflammation can damage joints and affect daily activities. Patients can learn more about rheumatoid arthritis and the importance of early, individualized care.

In some regions, sarilumab also has approval for specific other inflammatory conditions. Approved uses and prescribing guidance can differ by country, formulation and regulatory authority. A rheumatologist or other appropriate specialist can explain whether sarilumab is suitable for a person’s diagnosis and local treatment options.

How sarilumab works and what to expect

IL-6 has several roles in the body, including helping coordinate immune responses during infection. In rheumatoid arthritis, IL-6 activity can remain too high and sustain harmful inflammation. By blocking IL-6 receptors, sarilumab can reduce this inflammatory signaling and help improve joint symptoms and physical function.

Before treatment, clinicians review the person’s diagnosis, current symptoms, medical history, medications and infection risk. They may also discuss previous DMARDs, vaccination history, pregnancy plans and any history of bowel disease, liver disease or low blood cell counts. This shared decision-making process helps balance the likely benefits with potential risks.

During treatment, it is helpful to track joint symptoms, fatigue, stiffness, day-to-day function and any side effects. A person should not stop sarilumab, change the injection schedule or combine it with another immune-suppressing medicine unless their clinician advises this. Treatment plans often also include physical activity, joint protection and rehabilitation strategies where appropriate.

Before starting: screening, vaccines and monitoring

Because sarilumab affects immune function, clinicians generally check for active or previous infections before it is prescribed. This commonly includes assessment for tuberculosis and may include testing for hepatitis B and hepatitis C, based on medical history and local guidance. Sarilumab is generally not started in someone with a serious active infection.

Blood tests are needed before and during treatment. These may include a complete blood count, liver-function tests and cholesterol or lipid measurements. Sarilumab can lower certain white blood cells or platelets, affect liver test results and raise blood lipid levels. Regular monitoring allows the care team to identify changes early and adjust treatment if necessary.

Vaccinations should be reviewed before treatment begins. Inactivated vaccines may often be given when clinically appropriate, but live vaccines are usually avoided during treatment with sarilumab because the immune response is suppressed. Patients should ask their clinician about the timing of seasonal vaccines, travel vaccines and any vaccines they may have missed.

• Tell the clinician about past tuberculosis, hepatitis, repeated infections or recent close contact with someone who has tuberculosis.
• Provide a full list of medicines, including over-the-counter medicines, supplements and other biologic therapies.
• Discuss any planned surgery, dental procedure, pregnancy, breastfeeding or plans to conceive.

Possible side effects and important safety considerations

Like all medicines, sarilumab can cause side effects, although not everyone experiences them. Commonly reported effects can include injection-site reactions, upper respiratory symptoms, low white blood cell counts, changes in liver blood tests and increased cholesterol levels. These findings may not always cause noticeable symptoms, which is why scheduled laboratory monitoring matters.

The most important risk is infection. Sarilumab can make it harder for the body to fight infections and may reduce typical signs such as fever or a strong inflammatory response. Patients should inform their clinician about new cough, fever, chills, breathlessness, painful urination, skin sores, persistent diarrhea, unusual tiredness or other symptoms that could suggest infection.

Rare but serious complications can occur, including severe infection, serious allergic reaction and gastrointestinal perforation, a tear in the wall of the stomach or intestine. The latter risk may be higher in people with diverticulitis or who also use medicines such as corticosteroids or nonsteroidal anti-inflammatory drugs. Severe or persistent abdominal pain, especially with fever or a change in bowel habits, needs urgent medical assessment.

Sarilumab may interact with medicines whose processing in the body is influenced by inflammation levels. The prescriber and pharmacist should review all medicines carefully, including anticoagulants, certain cholesterol-lowering medicines and drugs with narrow dosing ranges. It is also generally not combined with other biologic DMARDs because this can increase infection risk without proven added benefit.

Using sarilumab safely at home

If self-injection is recommended, a nurse or clinician should provide practical training before the first home dose. The person should understand how to prepare the device, select an injection site, inject safely, rotate sites and dispose of used needles in a proper sharps container. The medicine should be stored and handled exactly as described in the product instructions.

Injection areas should be healthy skin, avoiding areas that are tender, bruised, scarred, red or affected by rash. It is sensible to keep a record of injection dates and to plan ahead for travel or prescription renewals. If a dose is missed, the safest next step is to contact the prescribing team or pharmacist for product-specific instructions rather than doubling a dose.

Healthy habits can support medical treatment but do not replace it. Regular low-impact movement, adequate sleep, stopping smoking where relevant and a balanced diet may support general wellbeing and joint function. For people with rheumatoid arthritis, guided exercise or physical therapy can help preserve mobility and confidence in daily activities.

When to seek medical care

Patients should contact their prescribing clinician promptly if they develop signs of infection, including fever, chills, a new or worsening cough, shortness of breath, painful urination, a persistent sore throat, skin redness or drainage, or unexplained fatigue. Medical advice is also important after exposure to chickenpox, shingles or tuberculosis, particularly if the person has not previously had these infections or vaccinations.

Urgent medical care is needed for symptoms of a serious allergic reaction, such as swelling of the lips, face or throat; difficulty breathing; widespread hives; or faintness. Severe abdominal pain, persistent vomiting, black or bloody stools, or fever with abdominal symptoms also requires urgent evaluation.

New bruising or bleeding, yellowing of the skin or eyes, marked weakness, or concerning changes in mood or health should be discussed with a healthcare professional. The care team may pause treatment, arrange blood tests or investigate another cause. Patients should not assume that a symptom is simply a routine effect of treatment.

Acibadem International’s multidisciplinary specialists and JCI-accredited hospitals assess and treat inflammatory conditions for international patients, with treatment decisions guided by individual clinical needs and ongoing monitoring.

Frequently asked questions

Is sarilumab a biologic medicine?

Yes. Sarilumab is a biologic DMARD that targets the IL-6 receptor, helping reduce immune-driven inflammation. It is different from conventional DMARDs because it acts on a specific immune pathway.

How long does sarilumab take to work?

Some people notice improvement within the first several weeks, but the full response can take longer. The prescribing clinician will assess symptoms, function and blood test results over time to decide whether treatment is working well enough.

Can sarilumab increase the risk of infection?

Yes. Sarilumab lowers part of the immune response, which can increase susceptibility to infections or make infections harder to recognize. Patients should report possible infection symptoms promptly and attend recommended screening and monitoring appointments.

Can vaccines be given while taking sarilumab?

Some non-live vaccines may be appropriate during treatment, but vaccine decisions should be made with the treating clinician. Live vaccines are generally avoided while using sarilumab because immune suppression can increase the risk of vaccine-related infection.

Do people taking sarilumab need blood tests?

Yes. Blood tests are usually performed before treatment and at intervals afterward to monitor blood cell counts, liver function and cholesterol levels. These tests help clinicians use the medicine as safely as possible.

Can sarilumab be used during pregnancy or breastfeeding?

The decision requires individualized medical advice because information on use during pregnancy and breastfeeding may be limited and recommendations can vary. Anyone who is pregnant, breastfeeding or planning pregnancy should discuss treatment options with their rheumatologist before starting or continuing sarilumab.

References

• U.S. Food and Drug Administration
• European Medicines Agency
• American College of Rheumatology
• National Institute for Health and Care Excellence
• Arthritis Foundation

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.